Molecular-based therapies for renal cell carcinoma.
The incidence of renal cell carcinoma (RCC) is rising steadily, but the ability to cure patients with metastatic RCC unfortunately remains limited. Emerging interest in gene therapy performance and safety is expressed by patients, medical institutes, and other agencies. It has become evident that better understanding of the genetic impairments and immune pathophysiology in RCC is essential for future improvement in patient care. Clinical trials now underway that are focusing on genetic and immune impairments will hopefully lead to future breakthroughs in RCC therapy. This paper reviews available gene therapies and other related therapeutic approaches for RCC and lists some of the current clinical trials focused on molecular-based therapies.
Zisman
A
A
University of California, School of Medicine, Department of Urology, Los Angeles 90095-1738, USA.
Pantuck
A J
AJ
Belldegrun
A S
AS
D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000628:therapy*; D008967:Molecular Biology